Global Digital Therapeutics Market to 2027
www.theinsightpartners.com
DIGITAL THERAPEUTICS MARKET To 2025 Global Analysis and Forecasts by Application (Diabetes, Cardiovascular Diseases, Central Nervous System (CNS) Disease, Respiratory Diseases, Smoking Cessation, Musculoskeletal Diseases, Others); Distribution Channel (Patients, Providers, Payers, and Employers) and Geography
1
Global Digital Therapeutics Market to 2027
www.theinsightpartners.com
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025. North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant rate in Asia Pacific (APAC) region during the forecast period. Factors such as, increasing prevalence of the chronic diseases, acceptance of the digital health platforms, developments performed by the market players in the countries such as India, China, Australia and others are likely to propel growth of the market. Market Insights Rising prevalence of chronic diseases to boost market growth Chronic diseases, including heart disease, stroke, diabetes, and obesity, are the leading causes of death in the world and account for most of the nation’s health care costs. According to report of CDC, in 2018, approximately more than 9% of the population has diabetes, which is the leading cause of kidney failure, lower-limb amputations in US. Moreover, the data also suggests that 1.5 million Americans are diagnosed with diabetes every year in the US. Similar trends for high presence of diabetes are prevalent around other geographies of the globe that include Asia Pacific, Europe, Middle East and Africa. For instance, according to IDF Diabetes Atlas published by the International Diabetes Federation in 2017, south-east Asia is home to approximately one-fifth (19%) of the total diabetes population worldwide. According to the report of American College of Cardiology Foundation, in 2018, Coronary heart disease (CHD) was the leading cause of deaths attributable to cardiovascular disease (CVD) in the US, which is followed by stroke (16.8%), high BP (9.4%), heart failure (HF) (9.0%), and other CVDs (17.9%). By 2035, approximately 130 million adults in the US population are projected to have some form of CVD. Thus, increasing geriatric population and related chronic diseases are expected to propel the growth of global digital therapeutics market over the forecast years. Get Sample PDF at https://www.theinsightpartners.com/sample/TIPHC00002236 Rising Pressure on Healthcare Providers to Reduce Healthcare Costs Digital therapeutics help in reducing the costs associated with chronic diseases, by helping an individual or an insurance provider to keep a track of one’s health status as well as track it with the help of digital means. As per American Diabetes Association, the estimated costs of diagnosed diabetes have risen to $327 billion in 2017, including $237 billion in direct medical costs and $90 billion in reduced productivity. This cost can be managed efficiently by including digital therapeutics that are offered by providers to help manage diabetes, can help patients get assistance with disease management and overcome the logistical challenges uncovered by the investigators. Application Insights The digital therapeutics market by application is segmented into diabetes, cardiovascular diseases, and central nervous system diseases, respiratory diseases, smoking cessation, musculoskeletal diseases and others. In 2017, the diabetes segment held a largest market share of 26.6% of the digital therapeutics, by application. This segment is also expected to dominate the market in 2025. The growth of the market is primarily attributed to the rising prevalence of diabetes
2
Global Digital Therapeutics Market to 2027
www.theinsightpartners.com
cases across the globe and also the segment is expected to grow with the fastest growth rate of 22.0% during the forecast period, 2018 to 2025. Distribution Channel Insights On the basis of distribution channel, the digital therapeutics market is segmented into patients, providers, payers, and employers. In 2017, the patients segment is expected to dominate the market based on the distribution channel contributing a share of 39.2%. This is primarily attributed to growing prevalence for the need to self-monitor as well as manage one’s health status. However, providers segment is anticipated to grow at a fastest growth rate of 21.3% during the forecast period. Strategic Insights Product launch/update and partnerships were observed as the most adopted strategy in global digital therapeutics industry. Few of the product approvals and partnerships made by the players in the market are listed below: 2017: In November, Propeller Health and Express Scripts entered into a partnership to provide Propeller’s FDA-cleared digital solutions to Express Scripts to manage asthma or COPD. 2016: In November, Propeller Health received FDA approval for its Propeller platform for use with GSK’s Ellipta inhaler. 2018: In April, Canary Health entered into a partnership with NMRHCA to offer the Better Choices, Better Health (BCBH) digital therapeutics program in New Mexico. 2016: In June, Canary Health partnered with Medtronic to expand their diabetes care offerings with Canary Health's selfmanagement suite for pre-diabetes, diabetes and related comorbidities. Inquire for Discount at https://www.theinsightpartners.com/discount/TIPHC00002236 DIGITAL THERAPEUTICS – MARKET SEGMENTATION By Application
Diabetes
Cardiovascular Diseases
Central Nervous System (CNS) Disease
Respiratory Diseases
Smoking Cessation
Musculoskeletal Diseases
Other Applications
3
Global Digital Therapeutics Market to 2027
www.theinsightpartners.com
By Distribution Channel
Patients
Providers
Payers
Employers
By Geography • North America
U.S.
Canada
Mexico
• Europe
France
Germany
UK
• Asia Pacific (APAC)
China
India
Japan
• Middle East & Africa (MEA)
Saudi Arabia
South Africa
UAE
• South America (SAM)
Brazil
4
Global Digital Therapeutics Market to 2027
www.theinsightpartners.com
Company Profiles
Propeller Health
CANARY HEALTH
Noom, Inc.
2Morrow Inc.
Livongo Health
Proteus Digital Health
WellDoc, Inc.
Fitbit, Inc.
Omada Health, Inc.
MANGO HEALTH
Buy this Report now at https://www.theinsightpartners.com/buy/TIPHC00002236
ABOUT US The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Technology, Media, and Telecommunication. Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis. Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, technology, products, and services etc., which helps our clients to gain a deeper analytical understanding of various research topics.
CONTACT US
5
Global Digital Therapeutics Market to 2027
www.theinsightpartners.com
If you have any queries about this report or would like further information, please contact us: North America:
+1 646 491 9876
Email:
sales@theinsightpartners.com
DISCLAIMER All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of the publisher, “The Insight Partners”. The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions, and recommendations that “The Insight Partners” delivers will be based on information gathered in good faith from primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, “The Insight Partners” can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect.
6